Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise
NCT04472494 · Bristol-Myers Squibb · PHASE2 · terminated · last registry update 2022-10-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual” | – | Registry record, Bristol-Myers Squibb |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD86 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-05-08Results posted on the registry: Columbia University, Abatacept + Adalimumab (NCT03619876)
- 2023-05-08Also stopped (terminated): Columbia University, Abatacept + Adalimumab (NCT03619876)
- 2023-04-21Results posted on the registry: Daniel Benjamin, Infliximab + Abatacept (NCT04593940)
- 2023-02-06Results posted on the registry: NYU Langone Health, Abatacept + DMARDs (NCT03652961)
- 2022-12-13Results posted on the registry: University of California, Los Angeles, Belatacept (NCT01953120)
- 2022-12-06Also stopped (withdrawn): University of California, San Francisco, Belatacept (NCT02939365)
- 2022-11-09Results posted on the registry: Brigham and Women's Hospital, Belatacept (NCT02327403)
- 2022-10-03Phase 3 first posted: Nantes University Hospital, Belatacept 250 Milligram Intravenous Powder for Solution (NCT05562869)
- 2022-08-29Results posted on the registry: George Washington University, Abatacept (NCT02594735)
- 2022-08-25Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor (NCT05515029)
- 2022-07-11Phase 3 first posted: Zhejiang Provincial People's Hospital, Janus Kinase Inhibitor + Abatacept (NCT05451615)
- 2022-06-23Phase 3 first posted: University Hospital, Montpellier, Abatacept (W12-W48) + TNF Inhibitor (W12-W48) (NCT05428488)
- 2022-04-20Phase 3 first posted: Massachusetts General Hospital, Abatacept plus + Placebo (NCT05335928)
- 2021-11-29Also stopped (terminated): Stuart Knechtle, M.D., Orencia® (Abatacept) (NCT04203875)
- 2021-11-02Results posted on the registry: Washington University School of Medicine, Belatacept + Tacrolimus (NCT03388008)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision